SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as the cannabis sector is gaining momentum amid discussions of potential federal policy changes, including reclassification of marijuana. The community is closely watching for announcements from the Trump administration and the Supreme Court, anticipating a short squeeze. Positive news around Redecan's new product launch is also contributing to the bullish sentiment.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is experiencing volatility following earnings, initially jumping on strong AI chip demand and guidance, but then declining due to profit-taking and concerns about non-AI revenue. The community is actively debating whether the pullback is a buying opportunity or a sign of an overvalued stock, with some pointing to potential gross margin compression and dependence on OpenAI revenue as causes for concern. Despite the mixed sentiment, underlying AI demand remains a key talking point, with analysts weighing in on future target prices.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors digest the potential impacts of both competitor Broadcom's earnings and news regarding AI chip exports to China. The community is actively discussing AMD's valuation, potential catalysts, and technical indicators for possible breakouts, with some focusing on long-term growth prospects. Some traders are also pointing to the potential of an island reversal.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors anticipate upcoming catalysts, including 48-week data and an FDA meeting, while closely monitoring the competitive landscape of MASH and obesity treatments. Community members are debating the potential impact of these events, with some expressing concerns about trial endpoints and others highlighting the company's leadership changes as a signal for a potential partnership or buyout. Discussions also revolve around efforts to manage expectations, counter misinformation, and interpret technical indicators amidst mixed opinions on the stock's near-term prospects.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending amidst high volatility and a wide range of community perspectives, with some traders citing the stock's low float and potential for a squeeze. Discussions revolve around a recent surge in price followed by a sharp decline, leaving investors debating whether to hold for a potential rebound or exit. The conversation also includes speculation about upcoming announcements, and potential catalysts.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending following a Q3 earnings beat, raised full-year guidance, and a significant buyback announcement, coupled with news of CEO succession plans. Community members are weighing in on the company's growth trajectory, potential analyst upgrades, and the impact of international sales, especially in China. Some traders are noting the potential for a short squeeze, while others are discussing the impact of leadership changes.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to community excitement around its low float and potential for a squeeze, drawing comparisons to other recent runners like $SMX.  Anticipation is building for news related to acquisitions and the company's crypto treasury, which some believe could act as a catalyst.  The stock's Hong Kong connection and potential undervaluation are also key talking points.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco's stock is trending as investors digest recent earnings and sales data, with community discussions focusing on whether the numbers justify the stock's valuation. While some highlight the company's strong membership model and digital growth, others point to a potential slowdown in membership growth and question the high P/E ratio compared to competitors. The community is also watching for any news on a potential special dividend or stock split, as well as the impact of an ongoing lawsuit regarding tariff refunds.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as discussions around cannabis reform intensify, with community members highlighting its potential role in the cultural shift. The project, built on Solana, is described as a culture coin with a focus on long-term growth and a strong community vibe. Some users are drawing parallels to Bitcoin, emphasizing Weedcoin's potential within the cannabis culture.

WorldFinancial

World Liberty Financial ($WLFI) is trending due to discussions around ALT5 Sigma's treasury strategy involving its $WLFI holdings and potential impacts on shareholder value. The community is focused on the yield-generating strategy for $WLFI, the possibility of ALT5 Sigma going private, and the upcoming RWA projects. Sentiment is mixed, with some expressing optimism about potential returns while others remain cautious, awaiting concrete financial results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $57.00

Citizens Jmp boosted their price objective on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a "market outperform" rating in a report on Thursday...

Research Analysts Set Expectations for TERN FY2027 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of Terns Pharmaceuticals in a research note...

Pharmaceutical Stocks To Follow Today - December 10th

Eli Lilly and Company, AbbVie, Pfizer, Novo Nordisk A/S, and Terns Pharmaceuticals are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...

Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Terns shares jumped after new Phase 1 data showed strong response rates and a continued favorable safety profile for TERN-701.</li><li>Updated results showed high 24-week molecular responses across doses with no loss of response and no dose-limiting toxicities.</li><li>The company said the findings support Phase 2 advancement, with deep responses seen even in patients previously failing multiple therapies.</li></ul>Terns Pharmaceuticals (TERN) shares jumped over 40% on Monday after the company reported additional positive Phase 1 results for its investigational chronic myeloid leukemia (CML) therapy TERN-701 at the 67th American Society of Hematology Annual Meeting.The biotech company said updated data from the ongoing CARDINAL trial showed a 64% major molecular response (MMR) rate by 24 weeks across all efficacy-evaluable patients, with a 75% MMR rate among those receiving doses above 320 mg once daily.&nbsp;The company said the treatment continued to show an encouraging safety and tolerability profile with longer exposure.<h2 class="st-heading-2">Terns Sets Phase 2 Doses&nbsp;</h2>CEO Amy Burroughs said the higher MMR rate at doses of 320 mg and 500 mg supports selection of those levels as recommended Phase 2 doses. She said study enrollment has surpassed 85 patients, enabling further progression into dose-expansion and pivotal studies.Chief Medical Officer Emil Kuriakose said the data include response achievements in patients who had previously experienced lack of efficacy on drugs such as Asciminib, Ponatinib and other tyrosine kinase inhibitors. He said the updated findings show deep molecular responses (DMR) at 24 weeks and a continued favorable safety profile across doses.<h2 class="st-heading-2">Strong 24-Week Response Rates</h2>As of the Sept. 13 cutoff, 63 patients had been enrolled across doses ranging from 160 mg to 500 mg. Among 38 efficacy-evaluable patients, the overall MMR rate by 24 weeks was 74%. No patients had lost MMR at the time of analysis.The company said the study population reflected heavily pretreated, refractory disease, including a median of three prior tyrosine kinase inhibitors (TKIs) and high rates of lack of efficacy to previous therapy.Safety data showed that 87% of patients remained on treatment, with no dose-limiting toxicities observed and no maximum tolerated dose reached. Most treatment-emergent adverse events were low grade, and rates of cytopenias were generally under 10%.<h2 class="st-heading-2">Responses At Higher Doses</h2>Among patients treated at doses of 320 mg or higher, the company reported an 80% overall MMR rate by 24 weeks in the efficacy-evaluable population. Deep molecular responses were observed across a wide range of baseline transcript levels.<h2 class="st-heading-2">Stocktwits Traders Cheer Momentum</h2>On Stocktwits, retail sentiment for Terns was ‘bullish’ amid ‘low’ message volume.<figure class="image"><img style="aspect-ratio:984/147;" src="https://news.stocktwits-cdn.com/terns_ss_png_43b9b42eb3.webp" alt="terns ss.png" width="984" height="147"><figcaption>TERN sentiment and message volume as of December 8| Source: Stocktwits</figcaption></figure>One user said, “congrats!&nbsp; Bio market is starting to have some movers. Good to see!”<stembedurl>https://stocktwits.com/Hard6and8/message/638531110</stembedurl>Another user urged investors to “buy it up.”<stembedurl>https://stocktwits.com/Whiskeyunderthebed/message/638530725</stembedurl><a href="https://stocktwits.com/symbol/TERN">Tern’s stock</a> has surged 620% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tern's stock (TERN) has surged 489% so far in 2025. (Photo credit: Getty Images)

Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients

New Phase 1 data showed strong response rates and a favorable safety profile for its experimental leukemia drug TERN-701.

Equity

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Time to Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up - Should You Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Here's Why

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Up 5.5% - Still a Buy...

Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High - Still a Buy?

Terns Pharmaceuticals (NASDAQ:TERN) Sets New 52-Week High - Should You Buy...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Rating of "Moderate Buy" from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat.com reports...

Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 5.7% - Time to Sell?

Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 5.7% - Time to Sell...

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.30	--	--	N/A
Q3 '25	-$0.30	-$0.27	9.02%	BEAT
Q2 '25	-$0.29	-$0.26	10.45%	BEAT
Q1 '25	-$0.29	-$0.26	11.54%	BEAT
Q4 '24	-$0.31	-$0.24	21.61%	BEAT

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TERN News

TERNTerns Pharmaceuticals Inc